- Home
- GDTC vs ALGS Comparison
GDTC vs ALGS Comparison
Compare GDTC & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDTC
- ALGS
- Stock Information
- Founded
- GDTC 2018
- ALGS 2018
- Country
- GDTC Singapore
- ALGS United States
- Employees
- GDTC N/A
- ALGS N/A
- Industry
- GDTC Biotechnology: Pharmaceutical Preparations
- ALGS Biotechnology: Pharmaceutical Preparations
- Sector
- GDTC Health Care
- ALGS Health Care
- Exchange
- GDTC Nasdaq
- ALGS Nasdaq
- Market Cap
- GDTC 23.7M
- ALGS 27.7M
- IPO Year
- GDTC 2023
- ALGS 2020
- Fundamental
- Price
- GDTC $2.13
- ALGS $7.21
- Analyst Decision
- GDTC Buy
- ALGS Strong Buy
- Analyst Count
- GDTC 1
- ALGS 1
- Target Price
- GDTC $5.00
- ALGS $75.00
- AVG Volume (30 Days)
- GDTC 12.4K
- ALGS 62.3K
- Earning Date
- GDTC 01-01-0001
- ALGS 10-31-2024
- Dividend Yield
- GDTC N/A
- ALGS N/A
- EPS Growth
- GDTC N/A
- ALGS N/A
- EPS
- GDTC N/A
- ALGS N/A
- Revenue
- GDTC $330,254.00
- ALGS $7,967,000.00
- Revenue This Year
- GDTC $4.46
- ALGS N/A
- Revenue Next Year
- GDTC N/A
- ALGS N/A
- P/E Ratio
- GDTC N/A
- ALGS N/A
- Revenue Growth
- GDTC N/A
- ALGS N/A
- 52 Week Low
- GDTC $1.20
- ALGS $6.76
- 52 Week High
- GDTC $5.50
- ALGS $30.00
- Technical
- Relative Strength Index (RSI)
- GDTC 69.51
- ALGS 36.55
- Support Level
- GDTC $1.96
- ALGS $6.84
- Resistance Level
- GDTC $2.16
- ALGS $7.85
- Average True Range (ATR)
- GDTC 0.15
- ALGS 0.71
- MACD
- GDTC 0.03
- ALGS 0.08
- Stochastic Oscillator
- GDTC 84.07
- ALGS 14.95
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.